HR Execs on the Move

Elicio

www.elicio.com

 
Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.elicio.com
  • 451 D Street 5th Floor, Suite 501
    Boston, MA USA 02210
  • Phone: 857.209.0050

Executives

Name Title Contact Details
Brian Piekos
 Chief Financial Officer Profile
Robert Connelly
 Chief Executive Officer Profile

Similar Companies

Oceanit Laboratories

Oceanit Laboratories, Inc. is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

UBC Heart + Lung Institute

UBC Heart + Lung Institute is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Finishing Touch Salon

Finishing Touch Salon is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellnetix

Cellnetix is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tris Pharma

Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies. Our mission is to understand the science of developing drug products with unique attributes, bring to market products that add value to our patients and customers, and provide a benefit to our company, employees and society at large.